ASAN vs PLAB

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and no available Altman Z-Score, limiting distress risk assessment. Despite strong gross margins and accelerating revenue and earnings growth, the company remains deeply unprofitable with negative ROE and ROA, high valuation multiples, and deteriorating insider sentiment. Aggressive insider selling, a bearish technical trend, and a significant disconnect between current price and analyst target further weigh on the outlook. While earnings surprises have been consistently positive, the overall risk profile remains elevated in a high-valuation, low-profitability context.

PLAB presents a dichotomy between a pristine balance sheet and concerning valuation/sentiment signals. While the Piotroski F-Score of 4/9 indicates stable health and the company maintains zero debt with exceptional liquidity, the stock's 157.8% one-year rally has outpaced its modest 6-8% growth rates. The current price of $45.84 is trading near its growth-based intrinsic value ($47.27) but significantly above its defensive Graham Number ($33.13). Heavy insider selling by the CEO and President, coupled with a high PEG ratio of 2.64, suggests the stock is currently overextended.